Legacy AI grade · Sources dated 2026-06-02. Not expert reviewed. Coverage is limited to the listed sources. About the new summary workflow

Redensyl for Androgenetic Alopecia

Verdict: Taiwan Regulatory Restriction

Across 2 PubMed studies, the evidence for Redensyl in Androgenetic Alopecia grades Tier C — weak evidence.

C 🟠 C Weak Evidence Taiwan Regulatory Restriction

🔬Why this grade7-layer evidence engine

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.43
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Taiwan Regulatory Restriction
Confidence
90%
Highly consistent evidence
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L11 AI re-checkIndependent read
0.30
L2 PubMedPrimary literature
0.40
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L5 Clinical bodiesAuthoritative stance
0.50
Against Mixed Supports
▸View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.427
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (2)L2 · primary research & systematic reviews

A randomized, single-blinded, vehicle-controlled study of a topical active blend in the treatment of androgenetic alopecia
PMID: 32473084 2020 RCT (single-blinded, vehicle-controlled) n = 44
Finding: Among patients on the active Redensyl+Sepicontrol lotion, the majority showed moderate improvement (reported as roughly great 7.7% / moderate 73.1% / stable 19.2% in active group), with the active arm outperforming vehicle. NOTE: this is a Redensyl-CONTAINING multi-ingredient blend (also Sepicontrol A5), single-blinded, with small n; it does NOT isolate Redensyl monotherapy effect.
🟠 Limited quality Effect size: Active blend > vehicle on global improvement (single-blind; effect not attributable to Redensyl alone; no isolated effect size for Redensyl reported)
View on PubMed
A Comparative Study of Topical Procapil With Platelet-Rich Plasma Therapy Versus Topical Redensyl, Saw Palmetto, and Biotin With Platelet-Rich Plasma Therapy in the Treatment of Androgenetic Alopecia
PMID: 37292551 2023 RCT (comparative, two active arms; no placebo) n = 54
Finding: AGA grading score differed significantly between groups (P<0.05); authors concluded PRP with adjuvant Redensyl + saw palmetto + biotin can be a better alternative to current PRP therapies. NOTE: Redensyl was combined with saw palmetto, biotin AND platelet-rich plasma — no vehicle/placebo arm and no isolation of Redensyl's individual contribution.
🟠 Limited quality Effect size: Between-group difference in AGA grade (P<0.05); no isolated Redensyl effect size; no placebo comparator
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

✓PMID 100% verifiedevery citation checked via NCBI Entrez
🔬2 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-androgenetic-alopecia-INT-redensyl-001 繁體中文版 →